Lakewood-Amedex Biotherapeutics, Inc.
LABT
$2.30
-$0.02-0.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 239.78% | 64.31% | 31.05% | -- | -- |
| Depreciation & Amortization | -4.00% | -12.73% | -23.81% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 145.98% | 20.08% | -6.32% | -- | -- |
| Operating Income | -145.98% | -20.08% | 6.32% | -- | -- |
| Income Before Tax | -84.33% | 3.63% | 20.76% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.33% | 3.63% | 20.76% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.33% | 3.63% | 20.76% | -- | -- |
| EBIT | -145.98% | -20.08% | 6.32% | -- | -- |
| EBITDA | -146.23% | -20.14% | 6.29% | -- | -- |
| EPS Basic | -13.94% | -4.53% | 0.62% | -- | -- |
| Normalized Basic EPS | -83.74% | -25.91% | -0.42% | -- | -- |
| EPS Diluted | -13.94% | -4.53% | 0.62% | -- | -- |
| Normalized Diluted EPS | -83.74% | -25.91% | -0.42% | -- | -- |
| Average Basic Shares Outstanding | 26.45% | 0.40% | 0.44% | -- | -- |
| Average Diluted Shares Outstanding | 26.45% | 0.40% | 0.44% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |